ArticleInvestigative ophthalmology & visual science2026
Early Prediction Model for Retinopathy of Prematurity Using Placental and Neonatal Risk Factors.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Existing prediction models for retinopathy of prematurity (ROP) primarily focus on screening reduction which occur 5 to 7 weeks after birth. We hypothesized that high-risk neonates could be identified much earlier if placental and early postnatal risk factors are incorporated, so that this high risk can be considered during neonatal treatment well before ROP screening begins. Methods: We included 591 neonates born ≤32 weeks of gestational age (GA) and/or birthweight (BW) ≤1500 grams. Data were retrospectively collected, and placentas were examined for histological abnormalities. The "Placenta as an Additional Predictor for ROP" (PAPROP) model included: GA, BW, mechanical ventilation, postnatal corticosteroids, severe histological chorioamnionitis, and distal villous hypoplasia. This model was internally validated with five-fold cross-validation and compared to a reference model using only GA and BW. Results: The PAPROP model had a discriminatory ability between ROP presence and absence of 0.81 (95% confidence interval [CI] = 0.76-0.86) compared to 0.78 in the reference GA&BW model. This model had a sensitivity of 0.97 and specificity of 0.44 in the test set (threshold 10%). Using clinically relevant thresholds of 10% to 15%, implementing this model in the second postnatal week could lead to a 25% reduction in ROP screenings without missing stage 2 and severe ROP. Conclusions: The PAPROP model has a high ability to predict ROP development at the end of the second postnatal week, has a potential high clinical utility, and is likely cost-effective. After further external validation, it may aid in creating a personalized neonatal treatment approach for ROP prevention in high-risk neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.